NTRK1 and acute myeloid leukemia: Quizartinib, an FMS - like tyrosine kinase 3 (FLT3) inhibitor, specifically blocks FLT3 receptor tyrosine kinase activity, suppressing downstream signaling pathways and preventing FLT3-ITD-mutant acute myeloid leukemia cells from proliferating and surviving while inducing apoptosis (33).